fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Adial Pharmaceuticals commences ONWARD trial of AD 04 as a therapeutic agent for the treatment of alcohol use disorder.

Written by | 26 Jun 2020

Adial Pharmaceuticals, Inc. announced that it has opened clinical trial sites and is recruiting trial subjects in Latvia after receiving all necessary approvals to commence the landmark ONWARD… read more.

Positive results from second phase III study evaluating once-daily relugolix combination therapy in women with endometriosis.- Myovant Sciences.

Written by | 26 Jun 2020

Myovant Sciences announced top-line results from SPIRIT 1, the second of two Phase III studies of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and… read more.

Adial Pharmaceuticals commences ONWARD trial of AD 04 as a therapeutic agent for the treatment of alcohol use disorder.

Written by | 26 Jun 2020

Adial Pharmaceuticals, Inc. announced that it has opened clinical trial sites and is recruiting trial subjects in Latvia after receiving all necessary approvals to commence the landmark ONWARD… read more.

FDA approves Fintepla to treat Dravet syndrome.- Zogenix

Written by | 26 Jun 2020

Zogenix, Inc. announced that the FDA has approved Fintepla (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.